The invention discloses application of a 
medicine in resisting Hantaan viruses, namely arbidol. The arbidol has obvious effect of inhibiting the Hantaan viruses 
in vitro, and the antivirus effect of 
drug administration before the viruses enter a 
cell is stronger than that of the 
drug administration after the viruses enter the 
cell. The concrete embodiment comprises the following: the 
drug administration is performed before and after the infection, the positive rate of 
virus-infected cells and the 
fluorescence intensity are reduced along with the concentration increase, and the 
medicine has 
dosage effect; and the 
medicine can obviously reduce the positive rate of 
virus infection, and the 
mRNA expression of the viruses is reduced. The arbidol has protection and 
treatment effect on the infection of the Hantaan viruses on a suckling mouse, and the protection effect is stronger than the 
treatment effect. The 
drug administration is performed within 24h before the infection; and with the increase of the dosage of the medicine, the death rate of the mouse is reduced, and the average survival days are extended. The 
drug administration within 24h after the infection can not improve the 
survival rate of an animal, but can extend the average survival days of the animal. The arbidol has the effect of inhibiting the Hantaan viruses in a body of the animal. The 
drug administration within 24h before the infection can lighten the 
pathologic change of tissues (
lung, 
kidney, and brain), and has 
treatment effect on HFRS. The medicine has prevention effect and also has treatment effect on patients with the hemorrhagic fever with renal syndrome (HFRS) caused by the Hantaan viruses, and no toxic 
side effect is found.